Ohm wrote: They can't do anything without data.
Post# of 148175
But if the FDA was working with the DSMC before the DSMC recommendations, surely they must have seen data -- or what else would they be talking about/working on?
I would have assumed the FDA and DSMC together came up with the idea of doing a 3/4 interim analysis.
Or if they saw no data, at least they would know that Leron was close to achieving statistical significance at the halfway point.... without knowing the actual numbers.